The National Institute of Allergy and Infectious Diseases (NIAID) is seeking to renew the IMPAc-TB program to accelerate tuberculosis vaccine development by characterizing protective immune responses and advancing research tools. The program will support research using human samples, animal models, and computational modeling, with a focus on tissue-specific and systemic immunity. Performance is expected to begin around September 1, 2027, with contracts lasting up to five years. The estimated total annual program cost is $10.5 million, with individual awards averaging approximately $5 million per year in total costs. The location for performance of services is not specified.